Teva Pharmaceuticals Surges to 458th in Trading Volume with 3.76 Billion Shares Exchanged

On April 9, 2025, Teva Pharmaceutical Industries Limited (TEVA) saw a significant surge in trading volume, with a total of 3.76 billion shares exchanged, marking a 121.39% increase from the previous day. This substantial trading activity placed Teva at the 458th position in terms of daily trading volume. The stock price of Teva also rose by 4.19%.

Teva, in collaboration with Samsung Bioepis, has launched Epysqli, a biosimilar version of Soliris. This new treatment offers a 30% discount compared to the original Soliris, providing a more affordable option for patients suffering from rare, life-threatening conditions such as atypical hemolytic uremic syndrome (aHUS), paroxysmal nocturnal hemoglobinuria, and generalized myasthenia gravis. Epysqli is authorized to treat these conditions, which are also approved indications for Soliris. The biosimilar is designed to be highly similar to Soliris in terms of purity, safety, and efficacy, and is marketed at a lower price point, similar to generic medications for traditional medicines.

Thomas Rainey, senior vice president of U.S. biosimilars at Teva, emphasized the importance of expanding access to life-enhancing medicines for individuals living with rare diseases. The launch of Epysqli in the U.S. is a significant step towards providing more affordable treatment options for underserved communities. Teva, under an agreement with Samsung Bioepis, will market Epysqli in the U.S. at a 30% reduced list price relative to Soliris, positioning it as one of the greatest cost-saving biosimilars to Soliris in the U.S. market.

Linda MacDonald, executive vice president and head of the global commercial division of Samsung Bioepis, highlighted the collaborative efforts between the two companies to ensure access to Epysqli for payers, healthcare professionals, and patients in the U.S. The availability of Epysqli means that patients now have an additional treatment option available at a lower cost, with proven quality, safety, and efficacy comparable to the reference product. The U.S. Food and Drug Administration approved Epysqli for aHUS based on clinical trial data showing similar pharmacological properties to Soliris in healthy volunteers and similar efficacy in people with PNH. However, due to the increased risk of serious meningococcal infections associated with complement inhibitors, Epysqli is only available in the U.S. through a restricted access program called Epysqli REMS.